Blueprint Medicines Director Shows Confidence with Major Stock Grant Acceptance

Rhea-AI Filing Summary

Blueprint Medicines Director Habib J. Dable received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, at a reference price of $128.12 per share. Following this transaction, Dable directly owns 12,644 shares of the company.

Key details of the RSU grant:

• Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
• Each RSU represents the right to receive one share of common stock upon vesting
• The transaction was reported via Form 4 filing, indicating changes in beneficial ownership

This equity grant appears to be part of the company's director compensation program, aligning the director's interests with those of shareholders through stock ownership. The filing was signed by Melissa Masse as attorney-in-fact on June 23, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dable Habib J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,902	$128.12	$500K

Holdings After Transaction: Common Stock — 12,644 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dable Habib J

(Last) (First) (Middle)

C/O BLUEPRINT MEDICINES CORPORATION

45 S

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Blueprint Medicines Corp [ BPMC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		3,902(1)	A	$128.12	12,644	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

	/s/ Melissa Masse, Attorney-in-Fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BPMC shares did Director Habib J Dable acquire on June 18, 2025?

Director Habib J Dable acquired 3,902 shares of BPMC common stock in the form of restricted stock units (RSUs) on June 18, 2025, at a price of $128.12 per share.

What are the vesting terms for BPMC Director Dable's June 2025 RSU grant?

The restricted stock units vest 100% on the earlier of (i) June 18, 2026 or (ii) the next annual meeting of Blueprint Medicines' stockholders. Each RSU represents a right to receive one share of common stock.

How many total BPMC shares does Habib Dable own after the June 2025 transaction?

Following the reported RSU grant transaction, Habib Dable beneficially owns 12,644 shares of Blueprint Medicines (BPMC) common stock directly.

What position does Habib Dable hold at BPMC according to the Form 4?

According to the Form 4 filing, Habib J Dable serves as a Director of Blueprint Medicines Corporation (BPMC), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.